Welcome to Roivant
Eyes

Reinventing the discovery, development, and commercialization of new medicines

About Us

We develop transformative medicines and technologies by building agile, focused companies called Vants.

Our companies

Our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

We employ technology across discovery, development, and commercialization.

Woman Rubbing Her Shoulder

Dermavant

Leading innovation in medical dermatology


Immunovant

Immunovant

Advancing potentially transformative therapies for autoimmune diseases


Scientist in Lab

Genevant

Delivering results through nucleic acids


Investor Update
video section decoration

Our CEO, Matt Gline, shares Roivant's progress and growth as VTAMA continues its positive impact on psoriasis patients, and Immunovant shares a new promising compound, IMVT-1402.

For Investors
For Investors

Learn more about our work

Sign up for our latest announcements and upcoming presentations

Pipeline
Pipeline

Advancing medicines that matter

View our broad and differentiated pipeline of investigational drugs.